H. pylori
Also called: Helicobacter pylori, stomach bacteria infection
Helicobacter pylori is a bacterium that lives in the stomach lining. In the UK prevalence is now below 15% and falling; most carriers have no symptoms. In a minority it causes gastritis, peptic ulcers, and rare cancers. Standard treatment is a 7 to 14 day course of two antibiotics plus a proton pump inhibitor, which clears the infection in many but not all cases on the first try, with success now often 80 percent or below where clarithromycin resistance is high.
Why it matters
H. pylori is the best-known bacterium able to thrive in stomach acid. It survives by burrowing into the stomach lining and producing urease, which neutralises acid locally. Most carriers are asymptomatic. But over decades, the immune response to H. pylori can damage the lining, producing chronic gastritis, peptic ulcers, and (rarely) gastric cancer or MALT lymphoma.
Symptoms when it does cause problems
- Burning pain in the upper abdomen, often worse on an empty stomach.
- Nausea, especially in the morning.
- Bloating and frequent burping.
- Loss of appetite and unexpected weight loss.
- Bad breath that does not respond to oral hygiene.
- Iron deficiency anaemia not explained by diet or periods.
Red flag symptoms
- Vomiting blood or stools that look black and tarry.
- Difficulty or pain on swallowing.
- Persistent vomiting.
- Significant unintentional weight loss.
- These warrant urgent referral and endoscopy.
How it is tested
- Urea breath test (most common, non-invasive).
- Stool antigen test.
- Endoscopy with biopsy (gold standard, used when symptoms suggest ulcer or cancer).
- Stop PPI medication for at least 2 weeks before testing or you will get a false negative.
- Stop antibiotics for at least 4 weeks before testing for the same reason.
Treatment
- First-line (NICE CKS): 7 day triple therapy. Non-penicillin-allergic: PPI + amoxicillin + clarithromycin OR PPI + amoxicillin + metronidazole (metronidazole is the alternative to clarithromycin, not a substitute for amoxicillin). Penicillin-allergic: PPI + clarithromycin + metronidazole.
- Second-line: 14 day quadruple therapy. PPI + bismuth + tetracycline + metronidazole.
- Confirm eradication with a follow-up urea breath test 4 weeks after finishing antibiotics.
- Resistance to clarithromycin is rising; some areas now start with the quadruple regimen.
- Re-infection rates after successful eradication are low (under 2 percent per year).
Common questions
- Can I have H. pylori without symptoms?
- Yes, most carriers do. Around 50 percent of the global population carry H. pylori; only 10 to 20 percent develop symptoms over their lifetime. Routine screening of asymptomatic adults is not currently recommended.
- Is H. pylori contagious?
- Mildly. Most transmission happens in childhood within families through shared food, saliva and water. Adult-to-adult transmission is uncommon. There is no need to isolate.
- Can probiotics treat H. pylori?
- Not on their own. Saccharomyces boulardii alongside antibiotics improves eradication rates by around 10 percent and reduces side effects of the antibiotics; single-strain Lactobacillus has not shown a clear eradication benefit. They are an adjunct, not a replacement.
- Does H. pylori cause IBS?
- Not directly. Some people with chronic H. pylori develop IBS-like symptoms that improve with eradication. Most IBS is unrelated to H. pylori. Test only if there are upper-GI symptoms.
Sources
- NICE CKS dyspepsia / proven peptic ulcer: H. pylori eradication regimens (first-line 7-day triple therapy, penicillin-allergic, second-line) (GPnotebook (NICE CKS summary))
- Maastricht VI/Florence consensus report on Helicobacter pylori management, Malfertheiner et al. 2022 (Gut (PMID 35944925))
- Helicobacter Pylori (Professional reference): UK prevalence below 15% and falling; asymptomatic carriage; re-infection rate (Patient.info / EMIS)
- Gastric Cancer chapter (Helicobacter pylori, NCBI Bookshelf): IARC/WHO 1994 Group 1 carcinogen classification (NCBI Bookshelf (Yamaoka, ed.))
- Burden of gastric cancer attributable to Helicobacter pylori in 27 countries, 2022 (more than two-thirds of cases attributable) (PMC)
- Update on triple therapy for eradication of H. pylori: standard triple therapy success now 80% or less; clarithromycin resistance (Ther Adv Gastroenterol (PMC3449761))
- H. pylori recurrence after successful eradication: annual recurrence 1.45% in developed countries (World J Gastroenterol (PMC2693738))
- S. boulardii as adjuvant therapy for H. pylori eradication: 11% eradication-rate increase (RR 1.11) (Front Cell Infect Microbiol (PMC11860874))
- Halitosis and H. pylori infection: a meta-analysis (OR 4.03; eradication reduces halitosis) (Medicine (Baltimore) (PMC5265885))
- H. pylori transmission routes and recurrence: predominantly acquired in childhood within families (Gastroenterol Res Pract (PMC6502203))